Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1168112 | 0.90 | MEN1 (0.80) | MEN1KMT2AMAPTNPSR1MAPK1 | |
| SCHEMBL5651574 | 0.89 | MEN1 (0.82) | MEN1KMT2AMAPTNPSR1MAPK1 | |
| SCHEMBL1167672 | 0.87 | MEN1 (0.47) | MEN1KMT2AMAPTNPSR1MAPK1 | |
| SCHEMBL14474303 | 0.80 | KMT2A (0.72) | MEN1KMT2AMAPTNPSR1MAPK1 | |
| SCHEMBL5653865 | 0.80 | MEN1 (0.84) | MEN1KMT2AMAPTNPSR1MAPK1 | |
| SCHEMBL1168581 | 0.79 | MEN1 (0.54) | MEN1KMT2AMAPTTP53SMN1; SMN2 | |
| SCHEMBL1167690 | 0.79 | KMT2A (1.00) | MEN1KMT2AMAPTNPSR1MAPK1 | |
| SCHEMBL30078294 | 0.79 | KMT2A (1.00) | MEN1KMT2AMAPTNPSR1MAPK1 | |
| SCHEMBL1168933 | 0.79 | MEN1 (0.82) | MEN1KMT2AMAPTNPSR1MAPK1 | |
| SCHEMBL1167512 | 0.78 | MEN1 (0.80) | MEN1KMT2AMAPTNPSR1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7250432-B2 | Pharmaceutical compositions of diaryl-isoxazole derivatives for the prevention and treatment of cancers | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2007-07-31 | — | — | US | claimed |
| US-7250432-B2 | Pharmaceutical compositions of diaryl-isoxazole derivatives for the prevention and treatment of cancers | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2007-07-31 | — | — | US | disclosed |
| WO-2006126751-A1 | NEW DIARYL-ISOXAZOLE DERIVATIVES, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME FOR THE PREVENTION AND THE TREATMENT OF CANCERS | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2006-11-30 | — | — | WO | disclosed |
| US-20050131036-A1 | Pharmaceutical compositions of diaryl-isoxazole derivatives for the prevention and treatment of cancers | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131036-A1 | Pharmaceutical compositions of diaryl-isoxazole derivatives for the prevention and treatment of cancers | UACA, SQLE, ALDH1A2 | MEN1 3914/4885KMT2A 4307/4885MAPT 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.